Digestive Diseases and Sciences

, Volume 58, Issue 5, pp 1185–1190 | Cite as

Donor-Transmitted Malignancy in a Liver Transplant Recipient: A Case Report and Review of Literature

  • Brian Kim
  • Tinsay Woreta
  • Po-Hung Chen
  • Berkeley Limketkai
  • Andrew Singer
  • Nabil Dagher
  • Andrew Cameron
  • Ming-Tseh Lin
  • Ihab Kamel
  • Ahmet Gurakar
Review

Abstract

Donor-transmitted malignancy is a rare complication of organ transplantation. This case illustrates a donor-transmitted adenocarcinoma in a patient 11 months after an orthotopic liver transplant for cryptogenic cirrhosis and hepatocellular carcinoma (HCC). Diagnosis of donor-transmitted malignancy may be challenging and can be confused with HCC recurrence. A timely diagnosis is crucial as a delay may limit treatment options. Biopsy of newly found liver lesions and the use of karyotypic and microsatellite analysis may be essential for diagnosis. Protocols should be in place to help recognize and limit the incidence of donor-transmitted malignancy.

Keywords

Liver transplant Donor-transmitted malignancy Microsatellite analysis Hepatocellular carcinoma 

References

  1. 1.
    McPhaul JJ, McIntosh DA. Tissue transplantation still vexes. N Engl Med. 1965;272:105.Google Scholar
  2. 2.
    Kauffman HM, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002;74:358–362.CrossRefGoogle Scholar
  3. 3.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl Med. 1996;334:693–699.CrossRefGoogle Scholar
  4. 4.
    Donovan JA, Simmons FA, Esrason KT, et al. Donor origin of a post-transplant liver allograft malignancy identified by fluorescence in situ hybridization for the Y chromosome and DNA genotyping. Transplantation. 1997;63:80–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Pfeiffer H, Ortmann C, Klein A, Brinkmann B. Origin of hepatocellular carcinoma recurring after allotransplantation revealed by microsatellite analysis. J Clin Pathol. 1997;50:792–794.PubMedCrossRefGoogle Scholar
  6. 6.
    Ng IOL, Shek TWH, Thung SN, et al. Microsatellite analysis in post-tranplantation lymphoproliferative disorder to determine donor/recipient origin. Mod Pathol. 2000;13:1180–1185.PubMedCrossRefGoogle Scholar
  7. 7.
    Kakar S, Burgart LJ, Charlton MR, Saito Y, Halling K, Thibodeau SN. Origin of adenocarcinoma in a transplanted liver determined by microsatelliteanalysis. Hum Pathol. 2002;33:435–436.PubMedCrossRefGoogle Scholar
  8. 8.
    Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant. 2011;11:1123–1130.PubMedCrossRefGoogle Scholar
  9. 9.
    Detry O, Honore P, Jacquet N. Management of recipients of hepatic allografts harvested from donors with malignancy diagnosed shortly after transplantation. Clin Tranplant. 1998;12:579–581.Google Scholar
  10. 10.
    Florman S, Bowne W, Kim-Schluger L, et al. Unresectable squamous cell carcinoma of donor origin treated with immunosuppression withdrawal and liver transplantation. Am J Transplant. 2003;4:278–282.CrossRefGoogle Scholar
  11. 11.
    Gray BN, Anderson JE, Burton MA, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust NZ J Surg. 1992;62:105–110.Google Scholar
  12. 12.
    Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation. 2002;74:1409–1413.PubMedCrossRefGoogle Scholar
  13. 13.
    Buell JF, Beebe TM, Trofe J, et al. Donor transmitted malignancies. Ann Transplant. 2004;9:53–56.PubMedGoogle Scholar
  14. 14.
    Nalesnik MA, Woodle ES, DiMaio JM, et al. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant. 2011;11:1140–1147.PubMedCrossRefGoogle Scholar
  15. 15.
    Lipschutz GS, Baxter-Lowe LA, Nguyen T, Jones KD, Ascher NL, Feng S. Death from donor-transmitted malignancy despite emergency liver transplantation. Liver Transplant. 2003;9:1102–1107.CrossRefGoogle Scholar
  16. 16.
    Fiorentino M, D’Errico A, Corti B, et al. A multiorgan donor cancer screening protocol: the Italian Emilia–Romagna region experience. Transplantation. 2003;76:1695–1699.PubMedCrossRefGoogle Scholar
  17. 17.
    Zucchini N, Fiorentino M, Grigioni AD, et al. The Italian multiorgan donor cancer screening protocol: 2002–2005 experience. Transplantation. 2008;85:S57–S60.PubMedCrossRefGoogle Scholar
  18. 18.
    Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.Google Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Brian Kim
    • 1
  • Tinsay Woreta
    • 1
  • Po-Hung Chen
    • 1
  • Berkeley Limketkai
    • 1
  • Andrew Singer
    • 2
  • Nabil Dagher
    • 2
  • Andrew Cameron
    • 2
  • Ming-Tseh Lin
    • 3
  • Ihab Kamel
    • 4
  • Ahmet Gurakar
    • 5
  1. 1.Division of Gastroenterology and Hepatology, Section of Transplant Hepatology, School of MedicineJohns Hopkins UniversityBaltimoreUSA
  2. 2.Section of Liver Transplant Surgery, School of MedicineJohns Hopkins UniversityBaltimoreUSA
  3. 3.Department of Pathology, School of MedicineJohns Hopkins UniversityBaltimoreUSA
  4. 4.Department of Radiology, School of MedicineJohns Hopkins UniversityBaltimoreUSA
  5. 5.Division of Gastroenterology and Hepatology, Section of Transplant Hepatology, School of MedicineJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations